CB1R mostly resides in the central nervous system (CNS) while the CB2R receptors are mostly expressed in the immune cells such as natural killer cells, neutrophils, and monocytes as well as other tissues such as the bladder, intestine, etc
A Phase I trial of the small non-peptide GLP-1 receptor agonist danuglipron in 98 patients with type 2 diabetes found that it had a similar glucose-lowering ability as the clinically used GLP-1 receptor agonists and was well tolerated during the 4 week study period [43]
Mitochondria have a bilayer membrane structure, which makes it difficult for some traditional drugs to penetrate
In the case of GLP-1 drugs, the most likely exemption could be for diabetes
Grab yours today
In dogs, supplementation has been associated with improved exercise performance and recovery in certain contexts, likely by supporting energy availability during activity